51 phenotypes from 12 alleles in 15 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Plcg2al/Plcg2al involves: 129 * C57BL/6	abnormal lymphatic vessel morphology	J:143529
	chylous ascites	J:143529
	internal hemorrhage	J:143529
	premature death	J:143529
Plcg2Ali5/Plcg2+ C3HeB/FeJ-Plcg2Ali5	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased B-2 B cell number	J:97930
	dermatitis	J:97930
	osteoarthritis	J:97930
Plcg2Ali5/Plcg2+ involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5	abnormal B cell physiology	J:97930
	glomerulonephritis	J:97930
	normal immune system phenotype	J:97930
Plcg2Ali5/Plcg2Ali5 involves: C57BL/6J * C3HeB/FeJ-Plcg2Ali5	abnormal B cell physiology	J:97930
	chronic inflammation	J:97930
	decreased mature B cell number	J:97930
	decreased transitional stage B cell number	J:97930
	glomerulonephritis	J:97930
Plcg2Ali14/Plcg2+ C3HeB/FeJ-Plcg2Ali14	abnormal foot pad morphology	J:166106
	abnormal inflammatory response	J:166106
Plcg2em1Msasn/Plcg2em1Msasn B6.Cg-Plcg2em1Msasn/J	abnormal calcium level	J:308279
	abnormal endocytosis	J:308279
	impaired macrophage phagocytosis	J:308279
Plcg2m1Btlr/Plcg2m1Btlr C57BL/6J-Plcg2m1Btlr	decreased IgM level	J:165702
Plcg2m1Btlr/Plcg2m1Btlr involves: C57BL/6J	abnormal B cell differentiation	J:185495
	decreased IgM level	J:185495
	normal immune system phenotype	J:185495
Plcg2M2Btlr/Plcg2+ C57BL/6J-Plcg2M2Btlr	decreased tumor necrosis factor secretion	J:218966
Plcg2M2Btlr/Plcg2M2Btlr C57BL/6J-Plcg2M2Btlr	decreased tumor necrosis factor secretion	J:218966
Plcg2M3Btlr/Plcg2M3Btlr C57BL/6J-Plcg2M3Btlr	abnormal humoral immune response	J:265101
	decreased B-1a cell number	J:265101
	decreased IgM level	J:265101
Plcg2m4Btlr/Plcg2m4Btlr C57BL/6J-Plcg2m4Btlr	decreased CD8-positive, naive alpha-beta T cell number	J:272862
	increased effector memory CD8-positive, alpha-beta T cell number	J:272862
Plcg2tm1.1Kuro/Plcg2tm1.1Kuro B6.Cg-Plcg2tm1.1Kuro	decreased interferon-gamma secretion	J:131621
	impaired natural killer cell mediated cytotoxicity	J:131621
Plcg2tm1.1Kuro/Plcg2tm1.1Kuro Not Specified	abnormal B cell differentiation	J:131161
	abnormal NK cell physiology	J:187430
	increased pro-B cell number	J:131161
	spleen hyperplasia	J:131161
Plcg2tm1Ichi/Plcg2tm1Ichi involves: 129 * C57BL/6	abnormal lymphatic vessel morphology	J:143529
	chylous ascites	J:143529
	internal hemorrhage	J:143529
	premature death	J:143529
Plcg2tm1Jni/Plcg2tm1Jni involves: 129P2/OlaHsd	abnormal B cell physiology	J:80614
	abnormal dendritic cell chemotaxis	J:157619
	abnormal dendritic cell morphology	J:157619
	abnormal dendritic cell physiology	J:157619
	arrested B cell differentiation	J:86373
	decreased B cell proliferation	J:80614
	decreased follicular B cell number	J:86373
	decreased mature B cell number	J:104166
	decreased platelet aggregation	J:114266
	decreased susceptibility to induced arthritis	J:157619
	increased B cell apoptosis	J:86373
	increased pro-B cell number	J:104166
	increased transitional stage T2 B cell number	J:86373
Plcg2tm1Jni/Plcg2tm1Jni involves: 129P2/OlaHsd * C57BL/6	abnormal B cell differentiation	J:117023
	abnormal B cell physiology	J:117023
	abnormal osteoclast differentiation	J:114607
	abnormal trabecular bone morphology	J:114607
	decreased interferon-gamma secretion	J:100716
	decreased osteoclast cell number	J:114607
	impaired natural killer cell mediated cytotoxicity	J:100716
	increased B cell proliferation	J:117023
	increased pre-B cell number	J:117023
	increased susceptibility to Herpesvirales infection	J:100716
	increased trabecular bone thickness	J:114607
	increased trabecular bone volume	J:114607
Plcg2tm1Kuro/Plcg2tm1Kuro Tg(Mx1-cre)1Cgn/0 involves: C57BL/6 * CBA	abnormal humoral immune response	J:63744
	decreased B cell proliferation	J:63744
	decreased mature B cell number	J:63744
	decreased pre-B cell number	J:63744
	normal immune system phenotype	J:63744
	increased B-1a cell number	J:63744
	increased immature B cell number	J:63744
	increased pro-B cell number	J:63744